# Anoat Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anoat-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Total disclosed funding: $2.2M
- Latest round: Seed (Jun 19, 2023)
- Investors on record: 1

## About

Based in Paris, France, Anoat Therapeutics formed in 2023 from a partnership between Inserm Transfert, Inserm’s technology transfer division, and AdBio partners. It operates as a preclinical-stage biotechnology company that specializes in developing novel therapies for cystic fibrosis. In June 2023, AdBio Partners led EUR 2 million in seed funding for Anoat Therapeutics. As of June 2023, the company is led by its CEO, Vincent Bischoff.  

Anoat Therapeutics is developing a comprehensive treatment for cystic fibrosis, a progressive inherited disorder that affects multiple organs, primarily the lungs and pancreas, and is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The company plans to use the seed funding for its pharmacology assessments.

## Funding rounds

- Seed, Jun 19, 2023, $2.2M — AdBio Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed